Health AI Central
Peer-Reviewed Publication
Rheumatol Ther2026October 15, 2026Journal Article

Effectiveness of Newly Initiated Tofacitinib and Biologic DMARDs in Patients with Rheumatoid Arthritis.

Katherine P Liao1, Chandrasekar Gopalakrishnan2, Jinoos Yazdany3, Suraj Sarvode Mothi2, Genevieve Gauthier4, Griffith Bell5, Arne Yndestad6, Milena A Gianfrancesco7
1Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
2OM1, Inc., Boston, MA, USA.
3Division of Rheumatology, School of Medicine, University of California, San Francisco, CA, USA.
4Pfizer Canada ULC, Kirkland, QC, Canada.
5Pfizer Inc, 66 Hudson Boulevard E, New York, NY, 10001, USA.
6Pfizer Inc, Oslo, Norway.
7Pfizer Inc, 66 Hudson Boulevard E, New York, NY, 10001, USA. Milena.Gianfrancesco@pfizer.com.
PubMed DOI

Abstract

INTRODUCTION: This new-user, active comparator study of patients with rheumatoid arthritis (RA) evaluated the real-world effectiveness of tofacitinib versus biologic disease-modifying antirheumatic drugs (bDMARDs) using data from the US OM1 PremiOM™ RA dataset. METHODS: This analysis included patients with RA aged ≥ 18 years initiating tofacitinib or bDMARDs (tumor necrosis factor inhibitors, TNF…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.